Harmonization of ANA testing challenge: quantification strategy to accurately predict end-point titers avoiding serial dilution.
Antinuclear antibody
Automated system
End-point titer
Fluorescence intensity
Indirect immunofluorescence
Journal
Immunologic research
ISSN: 1559-0755
Titre abrégé: Immunol Res
Pays: United States
ID NLM: 8611087
Informations de publication
Date de publication:
04 Oct 2023
04 Oct 2023
Historique:
received:
30
05
2023
accepted:
18
08
2023
medline:
4
10
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
aheadofprint
Résumé
Despite the advantages of automated systems for antinuclear antibody (ANA) analysis, the prediction of end-point titers avoiding serial dilutions is still in progress. The aims of this study were to set a conversion table providing discriminant ranges of fluorescence signal intensity values (FI) corresponding to the end-point titers and validate this tool in a real-life laboratory setting. Eight hundred ninety-four serum samples were analyzed for ANA using Image Navigator System. In order to classify FI into non-overlapping groups corresponding to conventional end-point titers, statistical discriminant analysis was used. Validation study was performed calculating agreement and error rates between visual readings and conversion table of 1119 routine ANA positive samples. Setting of FI ranges corresponding to the end-point titers for different staining patterns was computed. For samples showing single pattern, the overall agreement between visual readings and conversion table was 98.4% for all titers ranging from 1:160 to 1:2560, of which 68.0% had the same titer and 30.4% were within ± one titer difference. Concordance rates according to ANA patterns were as follows: (1) nuclear 98.4%, of which 67.0% had the same titer and 31.4% ± one titer; (2) cytoplasmic 100%, of which 72.7% had the same titer and 27.3% than ± one titer; (3) mitotic 66.6%, of which 33.3% had more ± one titer. Our study developed a quantification method for autoantibodies titers assessment based on just one single sample dilution instead of traditional serial dilution approach, providing significant advantages in routine laboratory in terms of reduction in hand-on time and harmonization of results.
Identifiants
pubmed: 37792145
doi: 10.1007/s12026-023-09417-w
pii: 10.1007/s12026-023-09417-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatology Ad Hoc Committee on Immunologic Testing. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47:434–44.
doi: 10.1002/art.10561
pubmed: 12209492
Bizzaro N, Wiik A. Appropriateness in anti-nuclear antibody testing: from clinical request to strategic laboratory practice. Clin Exp Rheumatol. 2004;22:349–55.
pubmed: 15144133
Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med. 2000;124:71–81.
doi: 10.5858/2000-124-0071-GFCUOT
pubmed: 10629135
Bizzaro N. Autoantibodies as predictors of disease: the clinical and experimental evidence. Autoimmun Rev. 2007;6:325–33.
doi: 10.1016/j.autrev.2007.01.006
pubmed: 17537376
Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. Autoantibodies 2015: from diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev. 2015;14:555–63.
doi: 10.1016/j.autrev.2015.01.017
pubmed: 25661979
Mahler M, Fritzler MJ. Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci. 2010;1183:267–87.
doi: 10.1111/j.1749-6632.2009.05127.x
pubmed: 20146721
Carbone T, Pafundi V, Tramontano G, Gilio M, Padula MC, Padula AA, D’Angelo S. Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort. Sci Rep. 2019;9(1):2177.
doi: 10.1038/s41598-019-38686-5
pubmed: 30778125
pmcid: 6379419
Wiik AS. Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol. 2005;34:260–8.
doi: 10.1080/03009740500202664
pubmed: 16195158
Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, Bossuyt X, Musset L, Cervera R, Plaza-Lopez A, Dias C, Sousa MJ, Radice A, Eriksson C, Hultgren O, Viander M, Khamashta M, Regenass S, Andrade LE, Wiik A, Tincani A, Rönnelid J, Bloch DB, Fritzler MJ, Chan EK, Garcia-De La Torre I, Konstantinov KN, Lahita R, Wilson M, Vainio O, Fabien N, Sinico RA, Meroni P, Shoenfeld Y. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73(1):17–23.
Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010;69(8):1420–2.
doi: 10.1136/ard.2009.127100
pubmed: 20511607
Hiemann R, Bu¨ttner T, Krieger T, Roggenbuck D, Sack U, Conrad K. Challenges of 417 automated screening and differentiation of non-organ specific autoantibodies 418 on HEp-2 cells. Autoimmun Rev. 2009;9:17–22.
doi: 10.1016/j.autrev.2009.02.033
pubmed: 19245860
Bizzaro N, Tozzoli R, Tonutti E, Piazza A, Manoni F, Ghirardello A, et al. Variability between methods to determine ANA, antidsDNA and anti-ENA autoantibodies: a collaborative study with the biomedical industry. J Immunol Methods. 1998;219:99–107.
doi: 10.1016/S0022-1759(98)00140-9
pubmed: 9831391
Song L, Hennink EJ, Young IT, Tanke HJ. Photobleaching kinetics of fluorescein in quantitative fluorescence microscopy. Biophys J. 1995;68:2588–600.
doi: 10.1016/S0006-3495(95)80442-X
pubmed: 7647262
pmcid: 1282169
Wiik AS, Bizzaro N. Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: it is all about the patient! Auto Immun Highlights. 2012;3(2):35–49.
doi: 10.1007/s13317-012-0029-0
pubmed: 26000126
pmcid: 4389069
Fritzler MJ. The antinuclear antibody test: last or lasting gasp? Arthritis Rheum. 2011;63(1):19–22.
doi: 10.1002/art.30078
pubmed: 20954183
Rigon A, Infantino M, Merone M, Iannello G, Tincani A, Cavazzana I, et al. The inter-observer reading variability in anti-nuclear antibodies indirect (ANA) immunofluorescence test: a multicenter evaluation and a review of the literature. Autoimmun Rev. 2017;16:1224–9.
doi: 10.1016/j.autrev.2017.10.006
pubmed: 29037905
Copple SS, Giles SR, Jaskowski TD, Gardiner AE, Wilson AM, Hill HR. Screening for IgG antinuclear autoantibodies by HEp-2 indirect fluorescent antibody assays and the need for standardization. Am J Clin Pathol. 2012;137:825–30.
doi: 10.1309/AJCPICNFG7UCES1S
pubmed: 22523223
Infantino M, Meacci F, Grossi V, Manfredi M, Benucci M, Merone M, et al. The burden of the variability introduced by the HEp-2 assay kit and the CAD system in ANA indirect immunofluorescence test. Immunol Res. 2017;65:345–54.
doi: 10.1007/s12026-016-8845-3
pubmed: 27456204
Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014;2014:315179.
doi: 10.1155/2014/315179
pubmed: 24868563
pmcid: 4020446
Tozzoli R, Antico A, Porcelli B, Bassetti D. Automation in indirect immunofluorescence testing: a new step in the evolution of the autoimmunology laboratory. Auto Immun Highlights. 2012;13(3):59–65.
doi: 10.1007/s13317-012-0035-2
Bizzaro N, Antico A, Platzgummer S, Tonutti E, Bassetti D, Pesente F, Tozzoli R, Tampoia M, Villalta D, Study Group on Autoimmune Diseases of the Italian Society of Laboratory Medicine, Italy. Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems. Autoimmun Rev. 2014;13:292–8.
doi: 10.1016/j.autrev.2013.10.015
pubmed: 24220268
van Beers JJBC, Hahn M, Fraune J, Mallet K, Krause C, Hormann W, Fechner K, Damoiseaux JGMC. Performance analysis of automated evaluation of antinuclear antibody indirect immunofluorescent tests in a routine setting. Auto Immun Highlights. 2018;9:8.
doi: 10.1007/s13317-018-0108-y
pubmed: 30238164
pmcid: 6147779
Copple SS, Jaskowski TD, Giles R, Hill HR. Interpretation of ANA indirect immunofluorescence test outside the darkroom using NOVA view compared to manual microscopy. J Immunol Res. 2014;2014:149316.
doi: 10.1155/2014/149316
pubmed: 24741573
pmcid: 3987884
Krause C, Ens K, Fechner K, Voigt J, Fraune J, Rohwäder E, Hahn M, Danckwardt M, Feirer C, Barth E, Martinetz T, Stöcker W. EUROPattern Suite technology for computer-aided immunofluorescence microscopy in autoantibody diagnostics. Lupus. 2015;24:516–29.
doi: 10.1177/0961203314559635
pubmed: 25801895
Van Hoovels L, Schouwers S, Van den Bremt S, Bogaert L, Vandeputte N, Vercammen M, Bossuyt X. Analytical performance of the single well titer function of NOVA View®: good enough to omit ANA IIF titer analysis? Clin Chem Lab Med. 2018;56:258–61.
doi: 10.1515/cclm-2018-0338
pubmed: 29804100
Meroni PL, Bizzaro N, Cavazzana I, Borghi MO, Tincani A. Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Med. 2014;3(12):38.
doi: 10.1186/1741-7015-12-38
Cinquanta L, Bizzaro N, Pesce G. Standardization and quality assessment under the perspective of automated computer-assisted HEp-2 immunofluorescence assay systems. Front Immunol. 2021;25(12):638863.
doi: 10.3389/fimmu.2021.638863
Van Hoovels L, Bossuyt X, Manfredi M, Grossi V, Benucci M, Van Den Bremt S, De Baere H, Franceschi D, Tosi E, Meoni M, Bizzaro N, Infantino M. Integrating quality assurance in autoimmunity: the changing face of the automated ANA IIF test. Clin Chem Lab Med. 2021;59:1247–55.
doi: 10.1515/cclm-2020-1669
pubmed: 33594844
Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PL, Fritzler MJ, Garcia-De La Torre I, Herold M, Mimori T, Satoh M, von Mühlen CA, Andrade LE. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. 2015;6:412.
Chan EK, Damoiseaux J, de Melo Cruvinel W, Carballo OG, Conrad K, Francescantonio PL, Fritzler MJ, Garcia-De La Torre I, Herold M, Mimori T, Satoh M, Mühlen CA von, Andrade LE. Report on the second international consensus on ANA pattern (ICAP) workshop in Dresden 2015. Lupus. 2016;25:797–804.
Andrade LEC, Klotz W, Herold M, Conrad K, Rönnelid J, Fritzler MJ, von Mühlen CA, Satoh M, Damoiseaux J, de MeloCruvinel W, Chan EKL, Executive Committee of ICAP. International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. Clin Chem Lab Med. 2018;56:1783–8.
doi: 10.1515/cclm-2018-0188
pubmed: 29813025
Herold M, Klotz W, Andrade LEC, Conrad K, de Melo CW, Damoiseaux J, Fritzler MJ, von Muhlen CA, Satoh M, Chan EKL. International consensus on antinuclear antibody patterns: defining negative results and reporting unidentified patterns. Clin Chem Lab Med. 2018;56:1799–802.
doi: 10.1515/cclm-2018-0052
pubmed: 29634478
Oyaert M, Bossuyt X, Ravelingien I, Van Hoovels L. Added value of indirect immunofluorescence intensity of automated antinuclear antibody testing in a secondary hospital setting. Clin Chem Lab Med. 2016;54:e63–6.
doi: 10.1515/cclm-2015-0887
pubmed: 26562037
Vulsteke JB, Van Hoovels L, Willems P, Vander Cruyssen B, Vanderschueren S, Westhovens R, Blockmans D, De Langhe E, Bossuyt X. Titre-specific positive predictive value of antinuclear antibody patterns. Ann Rheum Dis. 2021;80:e128.
doi: 10.1136/annrheumdis-2019-216245
pubmed: 31601627
Schouwers S, Bonnet M, Verschueren P, Westhovens R, Blockmans D, Mariën G, Bossuyt X. Value-added reporting of antinuclear antibody testing by automated indirect immunofluorescence analysis. Clin Chem Lab Med. 2014;52(4):547–51.
doi: 10.1515/cclm-2013-0610
pubmed: 24225130
Fierz W, Bossuyt X. Likelihood ratio approach and clinical interpretation of laboratory tests. Front Immunol. 2021;16(12):655262.
doi: 10.3389/fimmu.2021.655262
Bizzaro N, Bossuyt X, Haapala AM, Shoenfeld Y, Sack U. Accreditation in autoimmune diagnostic laboratories. A position paper of the European Autoimmunity Standardisation Initiative (EASI). Autoimmun Rev. 2017;16:81–6.
doi: 10.1016/j.autrev.2016.09.021
pubmed: 27666814
ISO 15189:2012. Medical laboratories — requirements for quality and competence. Geneva: ISO; 2012.
Sack U, Bossuyt X, Andreeva H, Antal-Szalmás P, Bizzaro N, Bogdanos D, European Autoimmunity Standardisation Initiative, et al. Quality and best practice in medical laboratories: specific requests for autoimmunity testing. Auto Immun Highlights. 2020;11:12.
doi: 10.1186/s13317-020-00134-0
pubmed: 32883353
pmcid: 7470612
Bogaert L, Van den Bremt S, Schouwers S, Bossuyt X, Van Hoovels L. Harmonizing by reducing inter-run variability: performance evaluation of a quality assurance program for antinuclear antibody detection by indirect immunofluorescence. Clin Chem Lab Med. 2019;57:990–8.
doi: 10.1515/cclm-2018-0933
pubmed: 30838836
Carbone T, Gilio M, Padula MC, Tramontano G, D’Angelo S, Pafundi V. A step towards standardization: a method for end-point titer determination by fluorescence index of an automated microscope. End-point titer determination by fluorescence index. J Immunol Methods. 2018;456:67–71.
doi: 10.1016/j.jim.2018.02.014
pubmed: 29470974
Choi HW, Kwon YJ, Park JH, Lee SY, Chun S, Won EJ, Lee JH, Choi HJ, Kim SH, Shin MG, Shin JH, Kee SJ. Evaluation of a fully automated antinuclear antibody indirect immunofluorescence assay in routine use. Front Immunol. 2020;4(11):607541.
doi: 10.3389/fimmu.2020.607541
Bonroy C, Vercammen M, Fierz W, Andrade LEC, Van Hoovels L, Infantino M, Fritzler MJ, Bogdanos D, Kozmar A, Nespola B, Broeders S, Patel D, Herold M, Zheng B, Chan EYT, Uibo R, Haapala AM, Musset L, Sack U, Nagy G, Sundic T, Fischer K, Rego de Sousa MJ, Vargas ML, Eriksson C, Heijnen I, García-De La Torre I, Carballo OG, Satoh M, Kim KH, Chan EKL, Damoiseaux J, Lopez-Hoyos M, Bossuyt X; European Federation of Laboratory Medicine (EFLM) Working Group “Autoimmunity Testing,” the European Autoimmune Standardization Initiative (EASI) and International Consensus on Antinuclear Antibody Patterns (ICAP). Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAP. Clin Chem Lab Med. 2023;61(7):1167–1198.
Chhabra S, Kumar Y, Kumar M, Sharma A, Bhardwaj R, Minz RW. Prevalence of autoantibodies to cellular cytoplasmic and mitotic antigens in routine antinuclear antibody reporting: implementation of international consensus on antinuclear antibodies patterns guidelines. Indian J Rheumatol. 2021;16(1):83–8.
doi: 10.4103/injr.injr_198_20